Matthew L. Posard, Director at HALOZYME THERAPEUTICS, INC. (HALO), sold 5,230 shares at $107.17 ($568K) on 2026-10-01, disclosed to the SEC on 2026-10-02.
Scheduled sale ($568k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $107.17 | 730 | $78K | 13.8% |
| 2 | $108.45 | 3,300 | $358K | 63.0% |
| 3 | $109.57 | 1,100 | $121K | 21.2% |
| 4 | $110.04 | 100 | $11K | 1.9% |
| Total | $108.54 avg | 5,230 | $568K | 100% |
| Filing → |
| HALO | SELL | 2024-06-13 | $1.0M | — | Filing → |
| HALO | SELL | 2022-12-06 | $1.7M | — | Filing → |
| NAUT | BUY | 2021-12-01 | $226K | — | Filing → |